Literature DB >> 29876733

Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy.

Bert Müller1, Janina Tatsios2, Jan Klonner2, Daniel Pilger2, Antonia M Joussen2.   

Abstract

PURPOSE: To evaluate the efficacy of navigated focal laser photocoagulation in patients with chronic central serous chorioretinopathy (CSCR) and active leakage on fluorescein angiography (FA).
METHODS: Thirty-two eyes of 32 patients (age 48 ± 11, m/f = 24/8) with persistent or recurrent CSCR (> 3 months) who received navigated laser photocoagulation (Navilas®) of leaking point(s) between June 2013 and 2016 were included in this retrospective case series. Outcome parameters after 4 weeks and 3 months were the number of patients presenting with complete resolution of subretinal fluid, the volume of subretinal fluid measured on SD-OCT (Spectralis Heidelberg Engineering©), and best corrected visual acuity (BCVA/ (Snellen equivalent).
RESULTS: Complete resolution of subretinal fluid was achieved in 17 eyes (50%) after 4 weeks and in 24 eyes (75%) after 3 months with an average number of 1.3 laser procedures (range 1-3). Five eyes displayed a nearly complete resolution with a reduction of over 80% of the subretinal fluid compared to baseline. Three eyes showed no reduction in subretinal fluid. BCVA improved from median 0.58 (range 0.16-1.25) to 0.66 (0.16-1.0) (p = 0.001). The seven patients who had been treated within the central 1 mm of the ETDRS-OCT Grid but outside the avascular foveal zone showed an improvement of BCVA from median 0.6 (range 0.2-1.0) to 0.8 (0.2-1.0). No patient experienced a treatment-induced visual loss.
CONCLUSIONS: Laser treatment with Navilas® using eye tracking and FA-based planning is a safe and effective alternative therapy in patients with chronic CSCR.

Entities:  

Keywords:  Central serous chorioretinopathy; Navigated laser photocoagulation

Mesh:

Year:  2018        PMID: 29876733     DOI: 10.1007/s00417-018-4031-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

1.  [Navigated focal retinal laser therapy using the NAVILAS® system for diabetic macula edema].

Authors:  M Kernt; R Cheuteu; R G Liegl; F Seidensticker; S Cserhati; C Hirneiss; C Haritoglou; A Kampik; M Ulbig; A S Neubauer
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

2.  Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study.

Authors:  Hem Kumar Tewari; Ritu Gadia; Deepak Kumar; Pradeep Venkatesh; Sat Pal Garg
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

3.  Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.

Authors:  Andrea Russo; Raffaele Turano; Francesco Morescalchi; Elena Gambicorti; Anna Cancarini; Sarah Duse; Ciro Costagliola; Francesco Semeraro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-10       Impact factor: 3.117

4.  Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy.

Authors:  Anne Rübsam; Claudia E Thieme; Juliane Schlomberg; Sibylle Winterhalter; Bert Müller; Antonia M Joussen; Nicole Stübiger
Journal:  J Ocul Pharmacol Ther       Date:  2017-03-09       Impact factor: 2.671

5.  Central serous chorioretinopathy treated with navigated retinal laser photocoagulation: visual acuity and retinal sensitivity.

Authors:  Leonardo Mastropasqua; Luca Di Antonio; Lisa Toto; Alessandra Mastropasqua; Angelo Di Iorio; Paolo Carpineto
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-03       Impact factor: 1.300

6.  Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.

Authors:  Massimo Nicoló; Chiara M Eandi; Camilla Alovisi; Federico M Grignolo; Carlo Enrico Traverso; Donatella Musetti; Felice Cardillo Piccolino
Journal:  Am J Ophthalmol       Date:  2014-01-30       Impact factor: 5.258

7.  Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study.

Authors:  P Lanzetta; F Furlan; L Morgante; D Veritti; F Bandello
Journal:  Eur J Ophthalmol       Date:  2008 Nov-Dec       Impact factor: 2.597

8.  Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage.

Authors:  San-Ni Chen; Jiunn-Feng Hwang; Li-Fang Tseng; Chun-Ju Lin
Journal:  Ophthalmology       Date:  2008-12       Impact factor: 12.079

9.  SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.

Authors:  Elodie Bousquet; Talal Beydoun; Pierre-Raphaël Rothschild; Ciara Bergin; Min Zhao; Rui Batista; Marie-Laure Brandely; Benedicte Couraud; Nicolette Farman; Alain Gaudric; François Chast; Francine Behar-Cohen
Journal:  Retina       Date:  2015-12       Impact factor: 4.256

10.  Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy.

Authors:  Shaik M Zakir; M Shukla; Zaka-Ur-Rab Simi; J Ahmad; Mahmood Sajid
Journal:  Indian J Ophthalmol       Date:  2009 Nov-Dec       Impact factor: 1.848

View more
  7 in total

1.  Automatic detection of leakage point in central serous chorioretinopathy of fundus fluorescein angiography based on time sequence deep learning.

Authors:  Menglu Chen; Kai Jin; Kun You; Yufeng Xu; Yao Wang; Chee-Chew Yip; Jian Wu; Juan Ye
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-12       Impact factor: 3.117

2.  Efficacy of Navigated Laser Photocoagulation for Chronic Central Serous Chorioretinopathy: A Retrospective Observational Study.

Authors:  Fen Zhou; Jin Yao; Qin Jiang; Weihua Yang
Journal:  Dis Markers       Date:  2022-04-20       Impact factor: 3.464

3.  Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy.

Authors:  Aliagha Alishiri; Khosrow Jadidi; Seyed Aliasghar Mosavi; Hamidreza Torabi
Journal:  J Curr Ophthalmol       Date:  2019-07-17

Review 4.  The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy.

Authors:  Stefano Da Pozzo; Pierluigi Iacono; Alessandro Arrigo; Maurizio Battaglia Parodi
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-29

5.  Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy.

Authors:  Lisa Toto; Rossella D'Aloisio; Chiara De Nicola; Federica Evangelista; Maria Ludovica Ruggeri; Luca Cerino; Maria Beatrice Simonelli; Agbéanda Aharrh-Gnama; Marta Di Nicola; Annamaria Porreca; Rodolfo Mastropasqua
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

6.  Intravitreal Dexamethasone Implant (IDI) Alone and Combined with Navigated 577 nm Subthreshold Micropulse Laser (SML) for Diabetic Macular Oedema.

Authors:  Lisa Toto; Rossella D'Aloisio; Alberto Quarta; Daniele Libertini; Giada D'Onofrio; Chiara De Nicola; Anna Romano; Rodolfo Mastropasqua
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

Review 7.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.